SPOTLIGHT: New HIV drugs lower virus levels

Early-stage clinical trials show that maraviroc, Pfizer's foray into a new class of anti-HIV drugs, significantly decreased levels of the virus in asymptomatic HIV-positive patients, according to data presented today at the 3rd International AIDS Society Conference. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.